Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients - Takeaways - MDSpire

Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients

  • By

  • Xichun Qin

  • Bo Cheng

  • Shangshang Ma

  • Kun Li

  • Yongfei Fan

  • Mingjun Li

  • Rangrang Wang

  • Xuefeng Ai

  • Leilei Wu

  • Xiucheng Liu

  • Xiaojin Wu

  • Dong Xie

  • November 17, 2025

  • 0 min

Share

  • 1

    Emotional distress (ED) is prevalent in non-small cell lung cancer (NSCLC) patients, significantly impacting their quality of life and treatment outcomes.

  • 2

    Chemotherapy after lung cancer surgery is associated with a higher risk of ED, affecting both mental health and recovery.

  • 3

    Tandospirone has been shown to alleviate ED symptoms and enhance the efficacy of cisplatin chemotherapy in NSCLC patients.

  • 4

    A study involving 1185 NSCLC patients revealed a 32.2% prevalence of ED post-surgery, compared to 8.9% in healthy controls.

  • 5

    Effective management of ED in lung cancer patients is crucial and may involve pharmacological treatments like tandospirone.

Original Source(s)

Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients

  • by Xichun Qin, Bo Cheng, Shangshang Ma, Kun Li, Yongfei Fan, Mingjun Li, Rangrang Wang, Xuefeng Ai, Leilei Wu, Xiucheng Liu, Xiaojin Wu, Dong Xie

  • November 17, 2025

Related Content

The Importance of Molecular Profiling in Delivering Guideline-Recommended Care—From Genetic Sequencing to Patient Outcomes

Exploring Lung Cancer Treatment Strategies within Brazil's Largest Private Health Insurance: Insights from Real-World Data

Worldwide Impact of Respiratory Cancers in 2022 and Projections for 2050: Incidence and Mortality Data from GLOBOCAN